Health Care & Life Sciences » Biotechnology | Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
317.00
317.00
1,101.00
2,050
Cost of Goods Sold (COGS) incl. D&A
258.00
602.00
-
-
-
Gross Income
258.00
285.00
-
-
-
SG&A Expense
13,177.00
29,535.00
47,007.00
54,260.00
64,742
EBIT
13,435.00
29,820.00
47,963.00
54,686.00
64,296
Pretax Income
13,431.00
29,818.00
47,743.00
54,010.00
62,279
Consolidated Net Income
13,431.00
29,818.00
47,743.00
54,010.00
62,279
Net Income
13,431.00
29,818.00
47,743.00
54,010.00
62,279
Net Income After Extraordinaries
13,431.00
29,818.00
47,743.00
54,010.00
62,279
Net Income Available to Common
15,642.00
34,752.00
51,424.00
54,010.00
62,279
EPS (Basic)
0.67
1.49
4.05
2.13
1.91
Basic Shares Outstanding
23,360.20
23,360.20
12,696.40
25,406.80
32,656.20
EPS (Diluted)
0.67
1.49
4.05
2.13
1.91
Diluted Shares Outstanding
23,360.20
23,360.20
12,696.40
25,406.80
32,656.20
EBITDA
13,177.00
29,218.00
46,690.00
53,159.00
62,692
Non-Operating Interest Income
4.00
2.00
220.00
676.00
2,017
Preferred Dividends
2,211.00
4,934.00
3,681.00
-
-

About Syros Pharmaceuticals

View Profile
Address
620 Memorial Drive
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.syros.com
Updated 07/08/2019
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.